While previous studies have reported a reduced risk of developing PD in diabetic patients using GLP-1 receptor agonists, likely due to improved glucose metabolism and reduced neuroinflammatory burden, it is important to note that the trials assessing their efficacy in managing PD and included in our analysis applied a diagnosis of diabetes as an exclusion criterion. Here, GLP1R is linked to Parkinson disease.